Socium Therapeutics is developing an orally-administered cancer vaccine platform based on a recombinant form of Salmonella typhi Ty21a, the same bacteria that has been safely used as the typhoid vaccine since 1989. Socium’s vaccine platform – CReST® (Cross-Presenting Recombinat Salmonella typhi Ty21a) – triggers a patient's immune system to kill cancer cells. Currently preparing for a Phase I trial of lead candidate in prostate cancer.